[O8] Oral Session 8　Lung Cancer / Thoracic Cancer 2（Immune Checkpoint Inhibitors）
【E】

[O8-1] First-line nivolumab + platinum chemotherapy + bevacizumab in advanced NSQ NSCLC: Subgroup analysis on OS in TASUKI-52

^○Naoki Inui¹, Shunichi Sugawara², Toyoaki Hida³, Tatsuya Yoshida⁴, Hiroshi Tanaka⁵, Toru Kumagai⁶, Terufumi Kato⁷, Shunsuke Teraoka⁸, Isamu Okamoto⁹, Yukio Hosomi¹⁰, Tatsuro Fukuhara¹¹, Go Naka¹², Nobuhiko Seki¹³, Makoto Nishio¹⁴, Yuichiro Ohe⁴, Tomohide Tamura¹⁵, Nobuyuki Yamamoto⁸, Hiroaki Akamatsu⁸, Shigeru Takahashi¹⁶, Kazuhiko Nakagawa¹⁷ (1.Department of Pulmonary Medicine, Hamamatsu University Hospital, 2.Department of Pulmonary Medicine, Sendai Kousei Hospital, 3.Department of Thoracic Oncology, Aichi Cancer Center, 4.Department of Thoracic Oncology, National Cancer Center Hospital, 5.Department of Internal Medicine, Niigata Cancer Center Hospital, 6.Department of Thoracic Oncology, Osaka International Cancer Institute, 7.Department of Thoracic Oncology, Kanagawa Cancer Center, 8.Internal Medicine III, Wakayama Medical University, 9.Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, 10.Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 11.Department of Respiratory Medicine, Miyagi Cancer Center, 12.Department of Respiratory Medicine, National Center for Global Health and Medicine, 13.Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, 14.Department of Thoracic Medical Oncology, Cancer Institute Hospital of JFCR, 15.Thoracic Center, St.Luke’s International Hospital, 16.Oncology Clinical Development Planning 1, Ono Pharmaceutical Co.,LTD., 17.Department of Medical Oncology, Kindai University Faculty of Medicine)